The invention provides HSP90β inhibitors comprising an antisense oligonucleotide targeting HSP90β, pharmaceutical compositions comprising said inhibitors and methods of treatment of a metabolic syndrome by administering said HSP90β inhibitors to a subject in need thereof. The antisense oligonucleotides may be targeted to skeletal muscle.
